Cargando…

The clinical outcomes of second-line chemotherapy in patients with advanced pancreatic cancer: a retrospective study

BACKGROUND: Despite recent advances in first-line chemotherapy for advanced pancreatic cancer, standard treatment after the failure of initial chemotherapy has not been established. Hence, we aimed to retrospectively analyze the clinical characteristics and outcomes of second-line chemotherapy in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Hyun yeb, Lee, Eun Mi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of Yeungnam Medical Science 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913911/ https://www.ncbi.nlm.nih.gov/pubmed/34663064 http://dx.doi.org/10.12701/yujm.2021.01347

Ejemplares similares

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
por: Lee, Jeung Eun, et al.
Publicado: (2020)

A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer
por: Ji, Sang Hoon, et al.
Publicado: (2009)

Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution
por: Lee, Seok Jeong, et al.
Publicado: (2014)

Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
por: Park, Se Jun, et al.
Publicado: (2019)

Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
por: Gränsmark, Emma, et al.
Publicado: (2020)

Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer
por: Blomstrand, Hakon, et al.
Publicado: (2021)

Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
por: Lee, Kyoungmin, et al.
Publicado: (2020)

First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis
por: Möhring, Christian, et al.
Publicado: (2021)

A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer
por: Cui, Hanzhi, et al.
Publicado: (2020)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer
por: Yeon, Sang Hoon, et al.
Publicado: (2023)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure
por: Kobayashi, Noritoshi, et al.
Publicado: (2017)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
por: Lee, Myung-Won, et al.
Publicado: (2020)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
por: Zaanan, Aziz, et al.
Publicado: (2014)

Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
por: Merz, Valeria, et al.
Publicado: (2020)

Retrospective Clinical Study of Advanced Pancreatic Cancer Treated With Chemotherapy and Abdominal Hyperthermia
por: Fan, Yu-Fei, et al.
Publicado: (2017)

Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis
por: Citterio, Chiara, et al.
Publicado: (2018)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

Clinical characteristics of second primary pancreatic cancer
por: Jo, Jung Hyun, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy
por: Shin, Kabsoo, et al.
Publicado: (2021)

The role of second-line chemotherapy in small cell lung cancer: a retrospective analysis
por: Zarogoulidis, Konstantinos, et al.
Publicado: (2013)

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
por: Fornaro, L, et al.
Publicado: (2014)

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
por: Ogawa, Kohei, et al.
Publicado: (2012)

Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis
por: Yoo, Changhoon, et al.
Publicado: (2019)

Retrospective analysis of the clinical and demographic variables on the outcomes after second-line treatment in advanced non-small cell lung cancer
por: Sau, Sourav, et al.
Publicado: (2013)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Systemic Chemotherapy in Advanced Pancreatic Cancer
por: Lee, Hee Seung, et al.
Publicado: (2016)

The Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer
por: Song, Ik-Chan, et al.
Publicado: (2015)

Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis
por: Lu, Wenjie, et al.
Publicado: (2022)

A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study
por: Choi, In Sil, et al.
Publicado: (2018)

Exceptional Response to Second-Line Gemcitabine/Nab-Paclitaxel Chemotherapy in Patients With Metastatic Pancreatic Adenocarcinoma
por: Bukhari, Nedal, et al.
Publicado: (2021)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Biweekly Irinotecan and Cisplatin as Second-line Chemotherapy in Pretreated Patients with Advanced Gastric Cancer: A Multicenter Phase II Study
por: Baek, Jin Ho, et al.
Publicado: (2005)

Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study
por: Kim, In-Ho, et al.
Publicado: (2021)

Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qjpsjaoapkebot8q3mkt17agls